We came across a bullish thesis on Exelixis, Inc. on Business Invest’s Substack by Francesco Ferrari. In this article, we will summarize the bulls’ thesis on EXEL. Exelixis, Inc.'s share was trading at $44.08 as of January 13th. EXEL’s trailing and forward P/E were 18.52 and 15.24 respectively according to Yahoo Finance.
[caption id="attachment_1127792" align="aligncenter" width="640"]Exelixis (EXEL) is a biopharmaceutical company focused on the discovery, development, and commercialization of oncology therapies, with...
Create a free account, or log in to read the full article
No credit card required.
We may use your email to send marketing emails about our services. Click here to read our privacy policy.